2026 Retina Market Update: Pharmaceutical Distributors Lead a New Phase of Consolidation
Is Now the Right Time to Sell Your Retina Practice?
Retina practices continue to attract significant interest from strategic acquirors, supported by an aging population, the rising prevalence of age-related macular degeneration and diabetic eye disease, and recurring treatment needs. The specialty’s substantial use of high-cost injectable therapies and robust clinical research pipeline add to its appeal, particularly for pharmaceutical distributors seeking to expand their specialty drug businesses and deepen relationships with physicians and manufacturers.
Pharmaceutical distributors’ interest in retina practices has reshaped the retina M&A landscape. The acquisitions of Retina Consultants of America (RCA) and PRISM Vision Holdings by major pharmaceutical distributors marked a shift from private equity ownership and introduced a new source of capital driving sector consolidation. Independent practices now face a more concentrated buyer universe, but one with substantial financial resources, longer investment horizons and strategic incentives to expand. The entry of pharmaceutical distributors creates compelling partnership opportunities while placing greater importance on how physicians evaluate potential buyers and transaction terms.
As pharmaceutical distributors enter the sector, the economics of operating a retina practice are becoming more complex. Biosimilar competition, payor step therapy, changing drug margins and longer-acting therapies are influencing revenue, profitability and working capital requirements. For retina physicians considering a transaction, understanding how biosimilar competition, payor step therapy, changing drug margins and longer-acting therapies intersect with a buyer’s partnership model is essential to evaluating upfront value, post-closing income and the long-term potential of retained equity.
Why Are Strategic Buyers Interested in Retina Practices?
Underlying demand for retina care is supported by favorable demographic and disease-prevalence trends. Wet AMD, diabetic retinopathy, DME and retinal vein occlusion disproportionately affect older and diabetic populations, both of which continue to grow. Intravitreal anti-VEGF utilization among Medicare beneficiaries increased substantially between 2014 and 2023, driven primarily by growth in aflibercept use and rapid adoption of faricimab.1 With a patient population heavily concentrated among Medicare beneficiaries and many retinal conditions requiring ongoing treatment over several years, practices have benefitted from highly recurring patient demand and predictable treatment volume.
The drug-centric nature of retina care has also fundamentally reshaped how buyers view the sector. Pharmaceutical distributors increasingly view retina practices as a strategic extension of their specialty distribution, group purchasing and clinical research businesses. Relationships with retina practices provide access to significant injectable drug volumes while expanding their presence across the specialty care ecosystem.
Clinical research represents an important driver of strategic interest. Retina remains an active area of ophthalmic drug development, and scaled platforms offer pharmaceutical sponsors access to large patient populations, established investigator networks and clinical trial infrastructure across multiple locations. RCA, for example, highlighted expanded access to clinical trials and research capabilities as a key benefit for EyeSouth retina physicians joining its network.2
Retina market dynamics have direct implications for independent retina practices. Although underlying patient demand and acquisition interest remain favorable, independent practices face financial and operational demands. Larger, well-capitalized platforms can leverage greater purchasing power, working capital capacity and centralized infrastructure to manage drug inventory, navigate evolving payor policies, support clinical research and recruit physicians. They can also spread the costs of revenue cycle management, credentialing, imaging technology and administrative functions across broader physician and location networks. Such capabilities can be difficult for smaller independent groups to replicate, particularly as drug inventory requirements and reimbursement complexity increase.
How Did Retina Become a Focus for Eye Care Investors?
Private equity’s first major push into eye care, beginning around 2017, focused on ophthalmology practices with a strong anterior segment focus. Cataract surgery, refractive procedures, and ambulatory surgery center ownership offered predictable, procedure-driven revenue, while optical and other ancillary services provided additional upside. Investors gravitated toward multispecialty platforms built around these anterior practices, viewing them as the most scalable and defensible foundation for consolidation.
Retina, by contrast, traded at a relative discount during this period due to the specialty’s dependence on drug revenue, concerns around the sustainability of drug margins, and more pronounced provider concentration risk. The first notable shift came when Quad-C invested in NJ Retina to form PRISM Vision in 2018. The thesis was centered around reverse vertical integration with retina serving as an anchor to layer on general ophthalmology and multispecialty practices. A few years later in 2020, Webster Equity Partners invested in Retina Consultants of America (RCA), to create the only pure-play retina platform in the country. RCA pursued a different strategy, aligning with many of the largest and most established retina practices to build a scaled, pure-play retina management services organization (MSO). As RCA grew, the market’s perception of retina shifted, and retina assets started commanding higher multiples. Many multispecialty platforms pivoted strategies as well and started to prioritize posterior segment practices as part of their growth playbook.
The landscape changed decisively in November 2024, when Cencora announced a definitive agreement to acquire RCA from Webster Equity Partners for approximately $4.6 billion in cash, with RCA’s affiliated practices, physicians and management retaining a minority interest and Cencora holding roughly 85% ownership. Cencora’s rationale spanned several factors.
Drug purchasing and distribution: Retina practices administer substantial volumes of high-cost injectable therapies. RCA gave Cencora a closer relationship with a large network of physicians whose practices align directly with its pharmaceutical distribution business.
A growing treatment market: Aging demographics, chronic retinal diseases and new therapies support ongoing demand and recurring treatment volume.
Clinical research and manufacturer relationships: RCA’s research network provides a channel for clinical trials and the introduction of new therapies, strengthening Cencora’s offering to pharmaceutical manufacturers.
A platform for further consolidation: RCA provided an established national organization through which Cencora could expand its practice management services and pursue additional acquisitions.
McKesson followed only months later, when in February 2025, it agreed to buy an 80% controlling interest in PRISM Vision Holdings from Quad-C for about $850 million. McKesson pointed to its track record in practice management and clinical research through its oncology platform as the expertise it intended to apply to retina and ophthalmology. The deal closed in April 2025, leaving two of the nation’s largest drug distributors controlling the two most prominent retina platforms and accelerating both consolidation and valuations across the sector.
Pharmaceutical distributor investment in physician practices is not unique to retina and has played out across other drug-intensive specialties where physician-administered therapies create a natural strategic fit for distributors. In oncology, McKesson has long operated The US Oncology Network, while Cencora acquired OneOncology earlier in 2026. Cardinal Health completed the acquisition of Integrated Oncology Network for $1.1 billion in December 2024 and a 73% ownership interest in GI Alliance for approximately $2.8 billion in January 2025, then completed the roughly $1.9 billion acquisition of Urology MSO Solaris Health in November 2025. PGP notes that connections between these specialties have become increasingly important across the drug supply chain because of the high-margin therapies involved.
Today, retina continues to be an attractive sector within the physician services market. The combination of demographic tailwinds, a deep therapeutic pipeline, research value, and strategic relevance to drug distributors has created an especially seller-friendly environment, with well-capitalized buyers competing for a finite pool of quality practices.
How Do Drug Economics and Payor Policies Affect Retina Practices?
While favorable market trends continue to support consolidation, shifts in the retina drug market are reshaping practice economics, with implications for both day-to-day operations and transaction value. Changes in drug pricing, reimbursement, treatment frequency and payor coverage are directly affecting practice revenue, margins, working capital requirements and patient volumes. A 2026 study of Medicare utilization found that standardized reimbursement per injection declined from approximately $1,234 to $725 for ranibizumab and from $1,527 to $1,380 for aflibercept between 2014 and 2023, even as annual aflibercept injection volumes nearly tripled.1 Accordingly, treatment volumes must be evaluated alongside drug mix and realized reimbursement to assess underlying profitability and enterprise value.
Several developments are reshaping the retina treatment landscape and underlying practice economics:
- Aflibercept Biosimilars: Amgen’s Pavblu was the first aflibercept biosimilar to reach the U.S. market, followed by Biocon’s August 2026 launch of Yesafili, an interchangeable Eylea 2 mg biosimilar priced at a wholesale acquisition cost (WAC) of $1,445.3 Additional entrants include Alvotech and Teva’s AVT06, with a potential launch as early as the fourth quarter of 2026, and Samsung Bioepis’ Opuviz, expected in January 2027.4 5 Under the Inflation Reduction Act, qualifying biosimilars receive Medicare reimbursement at ASP plus 8% of the reference product’s ASP, compared with the standard 6% add-on, for an applicable five-year period.[6] Increased biosimilar competition could alter purchasing economics, drug utilization and reimbursement spreads, making inventory management and drug-level profitability increasingly important.
- High-Dose and Longer-Acting Agents: The growing adoption of Roche’s Vabysmo and Regeneron’s Eylea HD reflects the shift toward therapies capable of extending treatment intervals. Eylea HD’s U.S. sales grew 52% year over year to $596 million in the second quarter of 2026, while original Eylea sales declined 36% year over year in the first quarter.7 8 9 Longer dosing intervals may improve patient convenience and free clinical capacity but could also reduce injection frequency and associated revenue per patient. The net financial impact will depend on drug mix, reimbursement, realized treatment intervals and the ability to redeploy available capacity.
- Payor Step Therapy: UnitedHealthcare’s Medicare Advantage Part B step therapy policy, effective October 1, 2026, designates Eylea, Eylea HD and Pavblu as preferred products for retinal conditions other than wet AMD, while Vabysmo, Lucentis and ranibizumab biosimilars are among the non-preferred alternatives.[10] Increasing payor influence over treatment selection introduces additional complexity into drug purchasing, inventory management and reimbursement, potentially creating meaningful variation in profitability across practices with different payor mixes.
- Sustained-Release Tyrosine Kinase Inhibitors (TKIs): Ocular Therapeutix’s Axpaxli met its primary endpoint in the Phase 3 SOL-1 trial, with 74.1% of patients maintaining vision at week 36 compared with 55.8% receiving aflibercept 2 mg, supporting the company’s planned regulatory submission.11 EyePoint’s Duravyu demonstrated a 42% reduction in treatment burden versus aflibercept in its Phase 3 LUGANO trial but subsequently failed to meet the primary endpoints in both pivotal wet AMD studies, prompting a shift in development priorities toward DME.12 These developments highlight both the potential for longer-acting therapies to reduce injection burden and the clinical and regulatory uncertainty surrounding their adoption.
- Geographic Atrophy (GA): Complement inhibitors Syfovre and Izervay have established a new treatment category, creating an incremental source of injection volume for retina practices. Syfovre generated $587 million in 2025 sales, and Biogen completed its approximately $5.6 billion acquisition of Apellis in May 2026.13 14 However, adoption has been tempered by modest efficacy and patient access challenges, while differences in patient selection, monitoring and reimbursement introduce additional considerations for practice economics.
- FDA-Approved Ophthalmic Bevacizumab: In July 2026, the FDA approved Outlook Therapeutics’ Lytenava (bevacizumab-vikg), the first FDA-approved ophthalmic formulation of bevacizumab for wet AMD, with a U.S. commercial launch expected before year-end.15 Its pricing, reimbursement and payor positioning relative to compounded bevacizumab and other anti-VEGF therapies could further influence drug utilization and practice margins.
- New Mechanisms and Gene Therapy: In September 2026, Merck reported that remigromig, a Wnt pathway agonist, met its primary endpoint of noninferiority to ranibizumab in the Phase 2b/3 BRUNELLO trial for DME, although certain adverse events and treatment discontinuations remain under evaluation.16 Three gene therapy candidates for wet AMD have also advanced into pivotal Phase 3 development, with anticipated topline readouts extending through 2027.17 While these approaches could eventually reduce treatment frequency and reshape care delivery, their commercial impact remains dependent on clinical efficacy, durability, safety, reimbursement and physician adoption.
For retina practice owners considering a sale, changes in drug pricing, reimbursement and treatment frequency make it increasingly important to demonstrate the durability of practice earnings rather than rely solely on historical growth. A clear understanding of drug-level profitability, payor exposure and evolving treatment patterns can help sellers substantiate valuation and address buyer concerns during diligence. Drug-level profitability, payor exposure and treatment patterns should also inform the evaluation of post-closing compensation and retained equity, particularly how future changes in drug economics will be shared between physicians and their partner.
How Can I Maximize the Value of My Retina Practice?
Buyers place significant emphasis on the sustainability of earnings, competitive market positioning, operational efficiency and opportunities for future growth. Based on PGP’s transaction experience in the space, the following characteristics generally position retina practices to generate stronger buyer interest and support attractive valuations:
- Scale and Market Density: Retina-focused buyers are typically attracted to practices with at least two retina physicians, with larger groups commanding additional interest based on their competitive market position, established referral networks and concentrated geographic footprint that supports operating efficiencies and market leadership.
- Physician Productivity: Efficient injection clinic workflows and high physician throughput that maximize clinical capacity and support operating leverage.
- Clinical Research: An established clinical research program with experienced coordinators, sponsor relationships and the infrastructure to support ongoing trial activity.
- Referral Relationships: Deep, diversified relationships with optometrists and comprehensive ophthalmologists that support consistent new patient volume and sustainable organic growth.
- Physician Alignment and Succession: A stable physician ownership group, strong associate base and established recruitment and succession plans that support retention, continuity of care and long-term growth.
Retina practices with these characteristics may command valuation multiples in the low double digits, supported by strong acquisition interest from McKesson- and Cencora-backed platforms, whose drug purchasing and distribution synergies can support premium pricing.
Why Sell a Retina Practice and How Are Deals Structured?
Independent retina practices pursue strategic partnerships to address a range of liquidity, operational and succession objectives. The relative importance of these goals varies based on a practice’s stage of development and its shareholders’ individual priorities. Understanding the motivations behind a potential transaction provides a foundation for evaluating whether and with whom to pursue a partnership.
Why Do Retina Physicians Explore Strategic Partnerships?
- Liquidity and Diversification: A transaction allows physician owners to monetize a portion of their ownership interest, generate upfront liquidity and diversify personal wealth away from a single asset exposed to reimbursement, drug pricing and operating risks.
- Subsequent Liquidity Events: Retained or rollover equity allows physicians to participate in future platform growth and potentially benefit from subsequent liquidity events. Each partner has its own mechanism to allow physicians to participate in growth.
- Operating Efficiencies and Physician Income: Scaled strategic partners can generate purchasing efficiencies, improved revenue cycle performance, enhanced payor contracting capabilities and administrative cost savings that help offset changes in post-transaction physician compensation. The extent to which these benefits translate into physician income depends on the partnership’s operating model and compensation structure.
- Infrastructure, Research and Succession: Strategic partners can provide access to physician recruitment, clinical research infrastructure, technology, capital and professional management resources. Partnerships may also create more flexible succession arrangements and reduce the financial burden of traditional equity buy-ins for incoming physicians.
How Are Retina Practice Transactions Structured?
While valuation often receives the most attention, transaction structures and partnership models can vary considerably by buyer. Physician compensation, rollover equity terms, opportunities for future liquidity, and the resources and operational involvement a partner brings can materially shape both the financial outcome and the experience of practicing after a transaction. Understanding how structure, compensation, liquidity and operational involvement differ by buyer is essential to selecting a partner that aligns with shareholders’ financial goals and clinical priorities.
Equity structure. Retained equity may take the form of ownership in a local joint venture or synthetic equity tied to the broader management services organization (MSO). Local equity generally links future value to the performance of the affiliated practice or regional business, while MSO-linked equity provides economic exposure to the broader platform. These structures can differ considerably in distribution rights, governance, dilution protections and how value is calculated upon exit.
Physician compensation. Some buyers offer compensation based on a percentage of collections, potentially in the 25–30% range, inclusive of drug-related collections and profits under the agreed formula. Others structure transactions around earnings before interest, taxes, depreciation, amortization and physician compensation (EBITAPC), with physicians accepting a compensation reduction, or “scrape,” to establish the earnings being acquired. Comparing these models requires evaluating both upfront proceeds and ongoing physician income, particularly how drug acquisition costs, rebates and changes in drug margins affect compensation.
Future liquidity. Opportunities to monetize retained equity may be governed by put and call arrangements that become exercisable after predefined periods and use specified valuation multiples or formulas. A put generally allows physicians to require the purchase of their equity, while a call allows the buyer to initiate that purchase. The timing, earnings definition, applicable multiple and payment terms can materially affect the value ultimately realized.
Resources and operational involvement. Buyers also differ in the support they provide and the degree of influence they exercise over practice operations. Some offer centralized purchasing, revenue cycle management, recruiting and clinical research infrastructure while preserving substantial local decision-making. Others pursue greater integration, making it important to understand how authority over staffing, scheduling, technology and growth investments will be shared after closing.
The most attractive offer is not always the one with the highest headline valuation. Physicians should evaluate upfront proceeds alongside ongoing compensation, the rights and liquidity associated with retained equity, and the partner’s approach to supporting and operating the practice. Assessing these elements together provides a clearer picture of the partnership’s long-term financial value and alignment with shareholder priorities.
What Do Recent Retina Transactions Tell Practice Owners?
The next phase of consolidation is expanding beyond acquisitions of independent retina groups. Pharmaceutical distributor-backed platforms are emerging as potential buyers of both retina divisions within larger ophthalmology organizations and, in the case of McKesson, entire multispecialty platforms, creating additional exit pathways for physician shareholders and private equity sponsors.
More recently, in March 2026, Cencora announced a definitive agreement to acquire EyeSouth Partners’ retina business for $1.1 billion, with affiliated retina physicians joining RCA.2 The transaction represents a carve-out from EyeSouth, an Olympus Partners-backed ophthalmology platform, and includes established retina practices such as Houston Retina Associates, Retina Institute of Illinois, Retina and Vitreous of Texas, University Retina and Macula Associates and Georgia Retina.18 Importantly, the transaction demonstrates the ability of pharmaceutical distributor-owned platforms to acquire retina operations separately from larger multispecialty ophthalmology organizations, expanding the buyer universe for independent groups with established retina service lines. PGP expects pharmaceutical distributor acquisitions of retina operations to continue across other multispecialty MSOs.
Strategic acquisition activity has also extended beyond retina-focused platforms. In August 2026, a Connecticut regulatory filing indicated that McKesson-owned PRISM was pursuing the acquisition of Blue Sea Capital-backed Spectrum Vision Partners, a multispecialty ophthalmology platform with more than 50 practices. While the transaction had not been formally announced by either party as of late August 2026, it further illustrates the potential for pharmaceutical distributor-owned platforms to serve as exit partners for mature private equity-backed multi-specialty ophthalmology platforms.19
The table below highlights select transactions involving retina practices and retina-focused platforms.
| Date | Buyer | Target | Description |
|---|---|---|---|
| Aug 2026 (Pending) | PRISM Vision Group (McKesson) | Spectrum Vision Partners | Blue Sea Capital-backed MSO with 50+ practices |
| Jun 2026 | Retina Consultants of America (Cencora) | South Carolina Retina Institute | Four-physician retina practice with four locations across coastal South Carolina, providing specialized medical and surgical care for retinal, macular and vitreous diseases. |
| May 2026 | PRISM Vision Group (McKesson) | Retina Macula Institute | Five-physician retina practice with two locations in Greater Los Angeles, offering specialized medical and surgical vitreoretinal care and clinical research. |
| Mar 2026 | Cencora / Retina Consultants of America | EyeSouth Partners – Retina Business | $1.1B acquisition of EyeSouth's retina operations; EyeSouth retains its non-retina ophthalmology and optometry businesses |
| Feb 2026 | Retina Consultants of America (Cencora) | Retinal Diagnostic Center | Six-physician retina practice with six locations across the San Francisco Bay Area, providing comprehensive diagnostic, medical and surgical vitreoretinal care with established clinical research capabilities. |
| Feb 2026 | Retina Consultants of America (Cencora) | Montana Retina Consultants | Two-physician retina practice based in Bozeman, providing specialized medical and surgical vitreoretinal care to patients across Southwest Montana. |
| Dec 2025 | EyeSouth Partners (Olympus Partners) | Vitreo Retinal Associates | Four-physician retina practice with three locations across North Central Florida, offering specialized vitreoretinal care, surgery and clinical research. |
| Nov 2025 | EyeSouth Partners (Olympus Partners) | Houston Retina Associates | Six-physician retina practice with seven locations across Greater Houston, specializing in the diagnosis and treatment of retinal, macular and vitreous diseases. |
| Nov 2025 | Retina Consultants of America (Cencora) | Retina-Vitreous Associates Medical Group | 11-physician retina practice with 11 locations across Greater Los Angeles, specializing in medical and surgical vitreoretinal care with an established clinical research program. |
| Oct 2025 | PRISM Vision Group (McKesson) | Spokane Eye Clinic | Leading multispecialty ophthalmology practice in the Inland Northwest with 25+ specialists across four locations, an ambulatory surgery center, three optical shops and clinical research capabilities. |
| Apr 2025 | McKesson Corporation | PRISM Vision Holdings | Acquired ~80% controlling interest for ~$850M from Quad-C; physicians retained ~20% ownership |
| Jan 2025 | Cencora, Inc. | Retina Consultants of America | Acquired ~85% controlling interest for ~$4.6B in cash plus up to $500M in contingent consideration |
PGP has deep experience in eye care, having advised on more than 17 transactions since its inception, a significant share of which involved a substantial retina component. Select transactions include:
- Spokane Eye Clinic in their strategic partnership with PRISM Vision Group, a portfolio company of McKesson Corporation.
- Kentucky Eye Institute in their strategic partnership with EyeSouth Partners.
- Associates in Ophthalmology in their strategic partnership with Spectrum Vision Partners.
- Northeast Ohio Eye Surgeons in their strategic partnership with Alpine Investors, to form Midwest Vision Partners.
- Ohio Eye Care Consultants in their strategic partnership with Alpine Investors, to form Midwest Vision Partners.
- Retina Macula Specialists of Miami in their partnership with New Orchard Capital, to form American Vision Group.
With several active mandates in the retina sector, PGP maintains real-time, proprietary insight into current retina market valuations, buyer appetite, and evolving deal terms, enabling PGP to position its clients’ retina practices effectively and maximize value at every stage of the process.
What Is PGP’s Perspective on the Retina Market?
Over the next 12–24 months, PGP expects continued acquisitions of independent retina practices, additional carve-outs of posterior segments from multispecialty organizations and selective consolidation among larger ophthalmology platforms. Competition for high-quality practices should remain strong, particularly for groups that offer geographic density, established research programs and a proven history of physician recruitment and growth.
As retina enters a new phase of consolidation, pharmaceutical distributor-backed platforms are bringing substantial capital and strategic incentives that make partnership increasingly compelling for independent practices. Distributor-backed capital and incentives create attractive partnership opportunities for independent retina practices that are distinctly different in approach. As such, it’s important to diligently evaluate how a partnership could impact your practice. Equally important as economics is culture, clinical philosophy, operational involvement and ability to deliver the resources promised. A carefully prepared, competitive process can help partners compare these trade-offs and select a partnership that supports both their financial objectives and the long-term success of the practice.
Interested in learning more about market insights, valuation trends, and strategic opportunities?
Speak to a Senior BankerSources & Citations
Physician Growth Partners · This content is provided for informational purposes only and does not constitute legal, financial, or investment advice. All transaction data sourced as cited. © 2026 Physician Growth Advisors, LLC. All rights reserved.
Latest Market Updates


Considering a healthcare transaction? Start with a confidential conversation.
"*" indicates required fields



